
109. ASCO 2024 - Early Breast Cancer
Oncology for the Inquisitive Mind · Michael Fernando and Josh Hurwitz
Audio is streamed directly from the publisher (sphinx.acast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examine four very interesting studies, looking at alternative immunotherapy strategies with adjuvant avelumab, adjuvant endocrine therapy omission in low-ER positive disease, ctDNA in predicting disease recurrence, and a study that aims to change the very bedrock of breast cancer classification. Lots to discuss, deconstruct and debate on today's episode!
Links to studies discussed (subscription may be required):
A-BRAVE: Link
Adjuvant ET omission in ER-low patients: Link
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC): Link
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at [email protected]
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.